YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 3, 2010, Pages 226-237

  Horbinski, Craig ^a   Wang, Guoji ^b   Wiley, Clayton A ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

10q; 1p19q; EGFR; Glioblastoma; Oligodendroglioma; YKL 40

Indexed keywords

CHI3L1 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; LECTIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GLIA; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; METABOLISM; MIDDLE AGED; OLIGODENDROGLIOMA; PATHOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; GLYCOPROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; NEUROGLIA; OLIGODENDROGLIOMA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953390586     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R and Wiley CA. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008; 173: 130-143.
2. Recklies AD, White C and Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase Bmediated signalling pathways. Biochem J 2002; 365: 119-126.
3. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA and Nordestgaard BG. Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. J Clin Oncol 2009; 27: 572-578.
4. Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K and Shozu M. Serum. YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009; 20: 71-77.
5. Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R and Atalay C. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 2008; 25: 801-809.
6. Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M, Ozkan F and Ozkan A. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol 2008; 26: 47-52.
7. Mylin AK, Abildgaard N, Johansen JS, Andersen NF, Heickendorff L, Standal T, Gimsing P and Knudsen LM. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol 2008; 80: 310-317.
8. Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA and Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer 2008; 122: 857-863.
9. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA and Christensen IJ. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007; 13: 3244-3249.
10. Kim SH, Das K, Noreen S, Coffman F and Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 2007; 5: 17.
11. Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H and Dupont J. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 2007; 104: 435-442.
12. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K and von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006; 106: 1130-1139.
13. Bergmann OJ, Johansen JS, Klausen TW, Mylin AK, Kristensen JS, Kjeldsen E and Johnsen HE. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin Cancer Res 2005; 11: 8644-8652.
14. Jensen BV, Johansen JS and Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res 2003; 9: 4423-4434.
15. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S and Nielsen HJ. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 2002; 95: 267-274.
16. Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL, Zhan WH, Wen JM and Guan XY. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 2009; 40: 1790-1797.
17. Tanwar MK, Gilbert MR and Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002; 62: 4364-4368.
18. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN and Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 2005; 11: 2258-2264.
19. Rousseau A, Nutt CL, Betensky RA, Iafrate AJ, Han M, Ligon KL, Rowitch DH and Louis DN. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 2006; 65: 1149-1156.
20. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, 3rd, Fuller GN and Aldape KD. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006; 12: 3935-3941.
21. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB and Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 11: 3326-3334.
22. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG and Aldape KD. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005; 65: 1678-1686.
23. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A and Hagedorn M. Experimental antiangiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 2008; 122: 2187-2198.
24. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, 2nd, Buckner JC, James CD and Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007; 25: 2288-2294.
25. Aldape K. Multiple markers increase overall predictive power as compared to any single marker (presentation). New Orleans: Society for Neuro-Oncology, 2009.
26. Junker N, Johansen JS, Hansen LT, Lund EL and Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005; 96: 183-190.
27. Wu Y, Siadaty MS, Berens ME, Hampton GM and Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 2008; 27: 6679-6689.
28. Kassem H, Sangar V, Cowan R, Clarke N and Margison GP. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 2002; 101: 454-460.
29. Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M and Aldape KD. Selective repression of YKL-40 by NF-kappaB in glioma cell lines in volves recruitment of histone deacetylase-1 and-2. FEBS Lett 2008; 582: 3193-3200.
30. Nutt CL. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg Focus 2005; 19: E2.
31. Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ and Chu CT. Chordoid Glioma: A Case Report and Molecular Characterization of Five Cases. Brain Pathol 2009; 19: 439-448.
32. Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL and Sposto R. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002; 346: 420-427.
33. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME and Gollin SM. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997; 57: 304-309.
34. Kleihues P and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999; 1: 44-51.
35. Iwata T, Kuwajima M, Sukeno A, Ishimaru N, Hayashi Y, Wabitsch M, Mizusawa N, Itakura M and Yoshimoto K. YKL-40 secreted from adipose tissue inhibits degradation of type I collagen. Biochem Biophys Res Commun 2009; 388: 511-516.
36. Hogdall EV, Ringsholt M, Hogdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Moller L, Price PA and Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009; 9: 8.
37. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B and Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009.(in press)
38. Ling H and Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004; 380: 651-659.
39. Badariotti F, Kypriotou M, Lelong C, Dubos MP, Renard E, Galera P and Favrel P. The phylogenetically conserved molluscan chitinase-like protein 1 (Cg-Clp1), homologue of human HCgp39, stimulates proliferation and regulates synthesis of extracellular matrix components of mammalian chondrocytes. J Biol Chem 2006; 281: 29583-29596.
40. Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D and Siegal T. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 2007; 13: 1429-1437.
41. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
42. Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S, Mokhtari K, Duffau H, Delattre JY and Hoang-Xuan K. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 2002; 97: 1397-1401.
43. Ueki K, Nishikawa R, Nakazato Y, Hirose T, Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, Ito S, Takahashi H, Mukasa A, Asai A and Kirino T. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002; 8: 196-201.